Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.43 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.43 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 4/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.39 |
| ▸ | TACR3 | P29371 | 1/20 | 0.39 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.38 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.38 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16328283 | 0.83 | HTT (0.44) | HTTLPAR1LPAR3HCAR2CTSK | |
| SCHEMBL10125211 | 0.78 | HCAR2 (0.53) | HTTLPAR1LPAR3HCAR2CTSK | |
| SCHEMBL10125207 | 0.78 | HCAR2 (0.53) | HTTLPAR1LPAR3HCAR2CTSK | |
| SCHEMBL15912310 | 0.78 | HCAR2 (0.53) | HTTLPAR1LPAR3HCAR2CTSK | |
| SCHEMBL12404553 | 0.77 | HSD17B10 (0.58) | HTTHSD17B10 | |
| SCHEMBL12412301 | 0.76 | HTT (0.38) | HTTCTSK | |
| SCHEMBL9829311 | 0.75 | HCAR2 (0.50) | HTTLPAR1LPAR3HCAR2CTSK | |
| SCHEMBL9829305 | 0.75 | HCAR2 (0.50) | HTTLPAR1LPAR3HCAR2CTSK | |
| SCHEMBL17465167 | 0.75 | HCAR2 (0.50) | HTTLPAR1LPAR3HCAR2OPRM1 | |
| SCHEMBL27666225 | 0.75 | HCAR2 (0.50) | HTTLPAR1LPAR3HCAR2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372873-B2 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-12 | — | — | US | disclosed |
| US-20110182856-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110182856-A1 | INHIBITORS OF SERINE PROTEASES | PRSS1, SPINT2, PRSS2 | HTT 3200/4885LPAR1 3998/4885LPAR3 4084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.